JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 16 No. 12 1115-1120
© 1975 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dubovsky, E. V.
Right arrow Articles by Tauxe, W. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dubovsky, E. V.
Right arrow Articles by Tauxe, W. N.

Comprehensive Evaluation of Renal Function in the Transplanted Kidney

E. V. Dubovsky, J. R. Logic, A. G. Diethelm, C. M. Balch and W. N. Tauxe

University of Alabama Medical Center, Birmingham, Alabama

Correspondence: For reprints contact: E. V. Dubovsky, Div. of Nuclear Medicine, University of Alabama Medical Center, Birmingham, Ala. 35294.

ABSTRACT

By means of a comprehensive renal function test based on the analysis of orthoiodohippurate kinetics carried out 223 times in 86 renal transplant patients, we have been able to separate clearly five clinical entities: normally functioning transplanted kidneys, acute tubular necrosis, cell-mediated rejection, humoral (chronic) rejection, and postrenal obstruction. Accurate prediction of the fate of the rejecting kidney can be made while still subclinical as much as a week before manifestations by other techniques are evident. Data on 22 donors studied 44 times are also presented. The comprehensive test consists of measurements of effective renal plasma flow (ERPF), sequential scintigraphy, calculations of excretory index (El) (percent dose actually found in bladder and voided urine as a fraction of the percent dose expected at a given time after injection at the patient's specific ERPF), and residual urine volume. Formulas and regression equations for the calculation of ERPF, El, residual urine, etc., are presented.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1975 by the Society of Nuclear Medicine.